Trial Profile
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi; Sanofi Pasteur
- 21 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 20 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.